drugset
drugset / Trial / NCT04729595

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

NCT04729595 ↗

Phase 2/3 Terminated 248 enrolled Adamis Pharmaceuticals Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.

Timeline

Start
2021-09-01
Primary completion
2022-09-21
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tempol Small molecule 400 mg —

Indications

COVID-19